Lediga tjänster Bli en del av Novartis, här kan du se mer om vilka karriärmöjligheter som finns.

Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search ...

Utforsk mulighetene hos Novartis og Sandoz her. Se mer informasjon om stillinger hos Novartis Gene Therapies på GTx Career Search.

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...

Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...

Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...

Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2 Sandoz continues to ...

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer ...

The preliminary results from the ongoing global phase III study STAND (NCT03814746) indicate no statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg and placebo ...

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma ...